Fig. 1: Screening of CD137 x PD-1/PD-L1 bAb combinations identifies MCLA-145. | Nature Communications

Fig. 1: Screening of CD137 x PD-1/PD-L1 bAb combinations identifies MCLA-145.

From: A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Fig. 1

a Left panel activity of CD137xPD-L1 and CD137xPD-1 bispecifics in a CD137 NFκB-luc reporter assay (fold induction of luciferase signal) Right panel experiment repeated with the addition of an Fc binding antibody; b Left panel levels of IL-2 released by activated T cells after 3 days of incubation with eight candidate CD137xPD-L1 bAb combinations in a dose titration in the presence of CHO-PD-L1 cells, Right panel, experiment repeated in the presence wildtype CHO cells; c levels of IL-2, IFNγ and TNFα released by activated T cells after 3 days of incubation with the three best performing CD137xPD-L1 bAbs and control antibodies in a dose titration in the presence of CHO-PD-L1 cells (bAb001 = MCLA-145).

Back to article page